WO2018030881A3 - Use of thyroid hormone for treatment of choroidal disease - Google Patents
Use of thyroid hormone for treatment of choroidal disease Download PDFInfo
- Publication number
- WO2018030881A3 WO2018030881A3 PCT/KR2017/012501 KR2017012501W WO2018030881A3 WO 2018030881 A3 WO2018030881 A3 WO 2018030881A3 KR 2017012501 W KR2017012501 W KR 2017012501W WO 2018030881 A3 WO2018030881 A3 WO 2018030881A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- thyroid hormone
- treatment
- choroidal disease
- choroidal
- disease
- Prior art date
Links
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 title abstract 4
- 208000027129 choroid disease Diseases 0.000 title abstract 4
- 239000005495 thyroid hormone Substances 0.000 title abstract 4
- 229940036555 thyroid hormone Drugs 0.000 title abstract 4
- 230000002265 prevention Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to a pharmaceutical composition containing a thyroid hormone for the prevention or treatment of a choroidal disease; a method for preventing or treating a choroidal disease by administering a thyroid hormone; and a novel use of a thyroid hormone for the prevention or treatment of a choroidal disease.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2017-0000841 | 2017-01-03 | ||
KR1020170000841A KR101782577B1 (en) | 2017-01-03 | 2017-01-03 | Use of thyroid hormone for treatment of choroid disease |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2018030881A2 WO2018030881A2 (en) | 2018-02-15 |
WO2018030881A3 true WO2018030881A3 (en) | 2018-03-29 |
Family
ID=60035899
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2017/012501 WO2018030881A2 (en) | 2017-01-03 | 2017-11-06 | Use of thyroid hormone for treatment of choroidal disease |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR101782577B1 (en) |
WO (1) | WO2018030881A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101782577B1 (en) * | 2017-01-03 | 2017-09-28 | 윤성문 | Use of thyroid hormone for treatment of choroid disease |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6075032A (en) * | 1995-02-01 | 2000-06-13 | Allergan | Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists |
WO2006031922A2 (en) * | 2004-09-15 | 2006-03-23 | Ordway Research Institute | Thyroid hormone analogs for promoting angiogenesis |
WO2009122180A1 (en) * | 2008-04-02 | 2009-10-08 | Medical Research Council | Pyrimidine derivatives capable of inhibiting one or more kinases |
KR101782577B1 (en) * | 2017-01-03 | 2017-09-28 | 윤성문 | Use of thyroid hormone for treatment of choroid disease |
-
2017
- 2017-01-03 KR KR1020170000841A patent/KR101782577B1/en active IP Right Grant
- 2017-11-06 WO PCT/KR2017/012501 patent/WO2018030881A2/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6075032A (en) * | 1995-02-01 | 2000-06-13 | Allergan | Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists |
WO2006031922A2 (en) * | 2004-09-15 | 2006-03-23 | Ordway Research Institute | Thyroid hormone analogs for promoting angiogenesis |
WO2009122180A1 (en) * | 2008-04-02 | 2009-10-08 | Medical Research Council | Pyrimidine derivatives capable of inhibiting one or more kinases |
KR101782577B1 (en) * | 2017-01-03 | 2017-09-28 | 윤성문 | Use of thyroid hormone for treatment of choroid disease |
Non-Patent Citations (1)
Title |
---|
SHI, L. Z.: "Use of Z310 cells as an in vitro blood-cerebrospinal fluid barrier model: Tight junction proteins and transport properties", TOXICOLOGY IN VITRO, vol. 22, no. 1, 28 July 2007 (2007-07-28), pages 190 - 199, XP022393682 * |
Also Published As
Publication number | Publication date |
---|---|
KR101782577B1 (en) | 2017-09-28 |
WO2018030881A2 (en) | 2018-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019012884A (en) | Combination therapy. | |
EP4223774A3 (en) | A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease | |
EA201691454A1 (en) | COMPOSITIONS OF PRIDOPIDININE MODIFIED SHIPPING | |
CR20190531A (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
WO2017022962A8 (en) | Composition for preventing or treating immune disease, comprising ripk inhibitor as active ingredient | |
MX2019011608A (en) | Substituted indoline derivatives as dengue viral replication inhibitors. | |
CR20190530A (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
MX2022002196A (en) | Niclosamide delayed-release composition and antiviral use thereof. | |
CR20220215A (en) | Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases | |
MA39765A (en) | Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use | |
MX2019001634A (en) | Amide compounds, pharmaceutical compositions thereof, and methods of using the same. | |
PH12019500618A1 (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease | |
MX2018009662A (en) | Method and pharmaceutical composition for treatment of neurodegeneration. | |
PH12016501548B1 (en) | Cholesteryl ester transfer protein (cetp) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases | |
MX2019012522A (en) | Therapeutic compounds and methods. | |
PH12020551117A1 (en) | Compositions for preventing or treating uveitis | |
MX2018002177A (en) | Novel catechol derivative and pharmaceutical composition comprising same. | |
WO2018030881A3 (en) | Use of thyroid hormone for treatment of choroidal disease | |
WO2020025657A9 (en) | Composition for use in the prevention and/or treatment of the genitourinary mucosa | |
MX2019008603A (en) | A pharmaceutical composition comprising an oxazine derivative and its use in the treatment or prevention of alzheimer's disease. | |
WO2015165964A8 (en) | Treatment and prevention of alzheimer's disease (ad) | |
MX2018006631A (en) | Compound for use in the prevention and treatment of neurodegenerative diseases. | |
MX2019004200A (en) | Combination therapy. | |
PH12020551620A1 (en) | Compositions for preventing or treating dry eye | |
MX2022002185A (en) | Aqueous pharmaceutical composition of anti-pd1 antibody prolgolimab and use thereof. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17839898 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17839898 Country of ref document: EP Kind code of ref document: A2 |